Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma.
Br J Haematol
; 204(2): 449-454, 2024 02.
Article
en En
| MEDLINE
| ID: mdl-38036424
ABSTRACT
Autologous patient-derived adoptive T-cell therapies have revolutionized the management of relapsed multiple myeloma (MM). However, the current manufacturing and quality control processes result in lengthy vein-to-vein time, making bridging therapy necessary for most patients. Yet the decision and choice of optimal bridging therapy are complex in the heavily pretreated relapsed MM patient. In this perspective piece, the authors provide their approach and considerations while selecting an optimal bridging regimen before autologous chimeric antigen receptor T-cell therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Receptores Quiméricos de Antígenos
/
Mieloma Múltiple
Límite:
Humans
Idioma:
En
Revista:
Br J Haematol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos